Noxopharm cancer drug secures Orphan Drug Designation from FDA
Outsourcing Pharma
APRIL 5, 2032
The Australian biotechnology company has been granted ODD status from the agency for Veyonda, a therapy intended for the treatment of soft-tissue sarcoma. Markets & Regulations
Let's personalize your content